UBS Group’s Provention Bio, Inc. Common Stock PRVB Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-320,038
| Closed | -$7.71M | – | 10362 |
|
|
2023
Q1 | $7.71M | Buy |
320,038
+276,789
| +640% | +$3.47M | ﹤0.01% | 2110 |
|
|
2022
Q4 | $457K | Buy |
43,249
+11,297
| +35% | +$91.2K | ﹤0.01% | 4782 |
|
|
2022
Q3 | $144K | Sell |
31,952
-326
| -1% | -$1.49K | ﹤0.01% | 5399 |
|
|
2022
Q2 | $129K | Sell |
32,278
-3,340
| -9% | -$15.8K | ﹤0.01% | 5233 |
|
|
2022
Q1 | $261K | Sell |
35,618
-2,258
| -6% | -$13.5K | ﹤0.01% | 5167 |
|
|
2021
Q4 | $213K | Buy |
37,876
+3,403
| +10% | +$21.6K | ﹤0.01% | 5632 |
|
|
2021
Q3 | $221K | Sell |
34,473
-2,555
| -7% | -$16.4K | ﹤0.01% | 5238 |
|
|
2021
Q2 | $312K | Sell |
37,028
-8,965
| -19% | -$72.3K | ﹤0.01% | 5063 |
|
|
2021
Q1 | $483K | Buy |
45,993
+10,997
| +31% | +$155K | ﹤0.01% | 4895 |
|
|
2020
Q4 | $593K | Sell |
34,996
-8,006
| -19% | -$120K | ﹤0.01% | 4477 |
|
|
2020
Q3 | $551K | Sell |
43,002
-3,791
| -8% | -$47.9K | ﹤0.01% | 4098 |
|
|
2020
Q2 | $660K | Buy |
46,793
+20,958
| +81% | +$265K | ﹤0.01% | 3907 |
|
|
2020
Q1 | $238K | Buy |
25,835
+4,996
| +24% | +$64.4K | ﹤0.01% | 4589 |
|
|
2019
Q4 | $311K | Buy |
20,839
+8,470
| +68% | +$75.5K | ﹤0.01% | 5254 |
|
|
2019
Q3 | $84K | Buy |
+12,369
| New | +$125K | ﹤0.01% | 5866 |
|
|
2018
Q4 | – | Sell |
-2,850
| Closed | -$11K | – | 8412 |
|
|
2018
Q3 | $11K | Buy |
+2,850
| New | +$11.3K | ﹤0.01% | 7135 |
|
Other funds holding PRVB
UBS Group's PRVB Position: Q2 2023 in Review
UBS Group sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 320,038 shares — an estimated $7.71M sold.
UBS Group first reported a position in PRVB in Q3 2018 and held it in 16 quarters. The position peaked at $7.71M in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.
- UBS Group reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
- UBS Group sold 320,038 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $7.71M.
- UBS Group first reported a position in Provention Bio, Inc. Common Stock in Q3 2018 and held it in 16 quarters.
- UBS Group's Provention Bio, Inc. Common Stock position peaked at $7.71M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.
Based on UBS Group's 13F filing for Q2 2023, filed 11 Aug 2023.